Aigen Investment Management LP acquired a new stake in Catalent, Inc. (NYSE:CTLT) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 5,957 shares of the company’s stock, valued at approximately $627,000.
Several other large investors have also made changes to their positions in CTLT. Norges Bank acquired a new position in shares of Catalent in the 4th quarter valued at about $149,074,000. AGF Investments Inc. bought a new stake in Catalent in the 4th quarter valued at about $75,616,000. BlackRock Inc. increased its position in Catalent by 5.3% in the 1st quarter. BlackRock Inc. now owns 13,988,761 shares of the company’s stock valued at $1,473,158,000 after buying an additional 701,908 shares in the last quarter. Thornburg Investment Management Inc. bought a new stake in Catalent in the 4th quarter valued at about $24,718,000. Finally, First Trust Advisors LP increased its position in Catalent by 183.6% in the 4th quarter. First Trust Advisors LP now owns 172,086 shares of the company’s stock valued at $17,909,000 after buying an additional 111,404 shares in the last quarter. 96.43% of the stock is currently owned by institutional investors.
In other news, CEO John R. Chiminski sold 42,220 shares of the business’s stock in a transaction that occurred on Thursday, March 18th. The stock was sold at an average price of $105.16, for a total value of $4,439,855.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Steven L. Fasman sold 21,647 shares of the business’s stock in a transaction that occurred on Thursday, March 18th. The stock was sold at an average price of $104.53, for a total value of $2,262,760.91. The disclosure for this sale can be found here. Insiders sold a total of 65,267 shares of company stock worth $6,850,694 in the last 90 days. Company insiders own 1.00% of the company’s stock.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, May 4th. The company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.08. Catalent had a return on equity of 13.88% and a net margin of 14.43%. The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $994.28 million. During the same period in the previous year, the company posted $0.50 EPS. The company’s revenue for the quarter was up 38.5% on a year-over-year basis. On average, analysts expect that Catalent, Inc. will post 2.7 earnings per share for the current year.
A number of analysts recently commented on the company. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $113.00 target price for the company in a research report on Friday, June 4th. Argus boosted their target price on Catalent from $130.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, March 2nd. They noted that the move was a valuation call. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $123.78.
Catalent Company Profile
Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
See Also: Bull Market
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.